Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple vaccine policy change save thousands of Children's lives?

NCT ID NCT01306006

Vaccine Sponsor: Bandim Health Project Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study in Guinea-Bissau tests a new policy: giving the measles vaccine to all children up to 35 months old, instead of only those under 12 months. Researchers think the vaccine may have extra health benefits beyond preventing measles, possibly cutting deaths by half. Around 3,500 children will be randomly assigned to either the current age-limited policy or the broader policy, and researchers will track who survives.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
measles vaccine
What this could lead to
If successful, this could show that giving measles vaccine to older children saves more lives than the current age-limited policy, potentially changing vaccination guidelines worldwide.
What could go wrong
This is a single-country study with 3500 children, and results may not apply elsewhere. The vaccine's non-specific effects are still not fully understood, and the trial cannot guarantee a 50% mortality reduction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 3,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2011

Finished

Dec 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

9 to 35 months

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 9-35 months, not yet received routine measles vaccination, resident in study area Exclusion Criteria: * To ill to be vaccinated (according to local practice)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mortality are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mortality Vaccines

Contacts and locations

Locations

  • Bandim Health Project

    Bissau, Guinea-Bissau

More trials for these conditions

Other studies related to the condition(s) this trial covers.